X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.

X4 Pharmaceuticals, Inc.

Leveraging our unparalleled expertise in diseases of the immune system and CXCR4 biology, we aim to bring innovative treatments to patients with chronic neutropenic disorders.

Our lead product candidate, mavorixafor, is a first-in-class CXCR4 inhibitor being developed as a once-daily, oral therapy for people with chronic neutropenic disorders. Mavorixafor has demonstrated the ability to mobilize immune cells from the bone marrow into the bloodstream, creating what we believe to be broad commercial potential in the estimated 50,000 (U.S.) diagnosed chronic neutropenia patients who currently have few to no treatment options.

We are currently evaluating the safety and efficacy of mavorixafor in a Phase 3 clinical trial for the treatment of people with WHIM syndrome; data from this Phase 3 study (4WHIM) are expected in the fourth quarter of 2022. We are also conducting a Phase 1b clinical trial of mavorixafor in people with idiopathic, cyclic, or congenital neutropenia. Based on positive data from the first part of this Phase 1b trial, we are currently amending and expanding the study to evaluate chronic use of daily oral mavorixafor with or without G-CSF in up to 50 participants with chronic neutropenic disorders. 

X4 is a public biopharmaceutical company (Nasdaq: XFOR) headquartered in Boston, Massachusetts, with a research center of excellence in Vienna, Austria.



Sio Capital Management

Abingworth

Altium Capital

Bain Capital Life Sciences

Lincoln Park Capital Fund

Monashee Investment Management

OrbiMed

Driehaus Capital Management

Ikarian Capital

X4 Pharmaceuticals

X4 was proud to participate in the American Society of Hematology #ASH23 conference and remains committed to raising awareness of #WHIMsyndrome, and the importance of early diagnosis, in the #hematology community.
 
If you suspect a patient could have WHIM syndrome, connect with X4 and access diagnosis resources at bit.ly/3FFTZTn
 
#classicalheme #hemeonc #immunology #immunedeficiency #WhatIfItsWHIM #chronicneutropenia #raredisease

This week, X4 is at the American Society of Hematology #ASH23 conference, connecting with hematologists to share disease education resources for diagnosing #WHIMsyndrome. WHIM is a rare hematologic disorder that may lead to debilitating or life-threatening complications.

Visit us at Booth 501 or find diagnosis resources including details about no-cost genetic testing at bit.ly/3FEoCbQ

#raredisease #hematology #classicalheme #hemeonc #immunology #immunedeficiency #WhatIfItsWHIM #chronicneutropenia


X4 is proud to be at the American Society of Hematology #ASH23 conference to raise awareness of #WHIMsyndrome and provide disease education resources to help facilitate diagnosis of patients living with this chronic hematologic disorder and combined primary immunodeficiency.

WHIM syndrome is a #raredisease frequently characterized by #chronicneutropenia, lymphopenia, recurrent infections, and hypogammaglobulinemia, with signs and symptoms that vary from patient to patient.

To learn more, visit us at Booth 501 or at bit.ly/3s8PkX8
#hematology #classicalheme #hemeonc #immunology #immunedeficiency #WhatIfItsWHIM



Are you attending the 65th American Society of Hematology annual meeting? Be sure to stop by our sponsored Industry Theater, “Classical Hematology: Looking Into the Future” on December 10th from 8:00 AM – 9:00 AM PST. Hope to see you there! #ASH23 

Thank you to The Boston Globe for recognizing us as a 2023 Top Place to Work! #X4tizens are the driving force behind what makes X4 exceptional. This recognition reflects our shared values as we bring hope to people with #rarediseases. Learn more here: https://brnw.ch/21wEWrj

	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue				3.50M -		3M -
cost of revenue					672K -		1.89M -	1.99M 5.39%	2.00M 0.10%
gross profit				3.50M -	-672K 119.20%	3M 546.43%	-1.89M 163.07%	-1.99M 5.39%	-2.00M 0.10%
selling and marketing expenses
general and administrative expenses	2.12M -	6.51M 207.46%	8.01M 22.87%	18.41M 129.93%	17.64M 4.16%	20.94M 18.72%	24.70M 17.95%
selling general and administrative expenses	2.12M -	6.51M 207.46%	8.01M 22.87%	18.41M 129.93%	17.64M 4.16%	20.94M 18.72%	24.70M 17.95%	27.02M 9.38%	35.51M 31.40%
research and development expenses	12.71M -	17.83M 40.34%	28.13M 57.75%	30.98M 10.14%	30.16M 2.63%	41.93M 39.02%	50.65M 20.78%	61.06M 20.56%	70.02M 14.68%
other expenses	-77K -	104K 235.06%	-16K 115.38%	-85K 431.25%	-1.10M 1,198.82%	-2.11M 91.03%	-3.57M 69.37%	-6.27M 75.53%
cost and expenses	12.67M -	21.96M 73.29%	32.27M 46.95%	46.21M 43.21%	47.80M 3.46%	62.87M 31.53%	75.35M 19.84%	88.08M 16.89%	107.52M 22.08%
operating expenses	12.67M -	21.96M 73.29%	32.27M 46.95%	46.21M 43.21%	47.80M 3.46%	62.87M 31.53%	75.35M 19.84%	88.08M 16.89%	105.53M 19.81%
interest expense	472K -	2.52M 432.84%	2.08M 17.34%	1.04M 50.02%	2.15M 106.64%	2.69M 25.20%	3.64M 35.49%	3.99M 9.64%	5.78M 44.68%
ebitda	-12.36M -	-21.57M 74.52%	-32.07M 48.69%	-41.83M 30.44%	-43.90M 4.96%	-59.87M 36.38%	-65.59M 9.55%	-88.59M 35.06%	-105.53M 19.12%
operating income	-14.82M -	-24.35M 64.22%	-36.13M 48.41%	-45.88M 26.99%	-51.70M 12.68%	-59.87M 15.80%	-85.11M 42.14%	-87.57M 2.89%	-107.52M 22.79%
depreciation and amortization	389K -	285K 26.74%	195K 31.58%	155K 20.51%	7.80M 4,932.26%	351K 95.50%	19.52M 5,460.11%	-1.02M 105.22%	2.00M 296.07%
total other income expenses net	-76K -	1.50M 2,068.42%	253K 83.09%	-85K 133.60%	-1.10M 1,198.82%	-2.11M 91.03%	-3.57M 69.37%	-6.27M 75.53%	6.43M 202.60%
income before tax	-13.22M -	-22.98M 73.82%	-33.88M 47.45%	-43.02M 26.99%	-52.81M 22.75%	-61.98M 17.38%	-88.68M 43.07%	-93.84M 5.82%	-101.09M 7.73%
income tax expense	395K -	2.62M 563.04%	1.87M 28.68%	3.90M 108.94%	3.80M 2.72%	148K 96.10%	17K 88.51%	28K 64.71%	78K 178.57%
net income	-13.22M -	-22.98M 73.82%	-33.88M 47.45%	-43.02M 26.99%	-56.60M 31.57%	-62.13M 9.76%	-88.70M 42.76%	-93.87M 5.83%	-101.17M 7.78%
weighted average shs out	928.01K -	928.01K 0%	343.64K 62.97%	459K 33.57%	11.53M 2,411.98%	20.08M 74.13%	25.75M 28.25%	63.53M 146.71%	177.81M 179.91%
weighted average shs out dil	928.01K -	928.01K 0%	343.64K 62.97%	459K 33.57%	11.53M 2,411.98%	20.08M 74.13%	25.75M 28.25%	63.53M 146.71%	177.81M 179.91%
eps	-14.24 -	-24.76 73.88%	-98.58 298.14%	-93.73 4.92%	-4.91 94.76%	-3.09 37.07%	-3.44 11.33%	-1.48 56.98%	-0.57 61.49%
epsdiluted	-14.24 -	-24.76 73.88%	-98.58 298.14%	-93.73 4.92%	-4.91 94.76%	-3.09 37.07%	-3.44 11.33%	-1.48 56.98%	-0.57 61.49%

NASDAQ:XFOR

X4 Pharmaceuticals

Last Close

0.69

30/08 20:00

Market Cap

103.11M

Beta: 0.25

Volume Today

726.85K

Avg: 1.81M

PE Ratio

−1.27

PFCF: −1.65

Preview